The 5th ISCC
November 29-30, 2000
Keidanren Hall
Program November 29, 2000 (Wed)
09:30 - 9:35
Haruo Sugano (Cancer Chemotherapy Center, Tokyo, Japan)
Welcome and Introduction
I Genetic Approaches for Drug Discovery
Chairpersons: Paul Workman (Inst. Cancer Res., Sutton Surrey, U.K.)
Takashi Tsuruo (Univ. Tokyo, Tokyo, Japan)
09:35 - 10:05
Neil W. Gibson (Bayer Co., West Haven, USA)
Drug discovery in the new Millennium
10:05 - 10:25
Yusuke Nakamura (Univ. Tokyo, Tokyo, Japan)
p53-target genes
10:25 - 10:55
Paul Workman (Inst. Cancer Res., Sutton Surrey, UK)
Exploiting the molecular abnormalities responsible for cancer: Signal transduction drugs
10:55 - 11:05
Discussion
11:05 - 11:25
Coffee Break
11:25 - 11:45
Minoru Yoshida (Univ. Tokyo, Tokyo, Japan)
Histone deacetylase inhibitors--Discovery and coming generation
11:45 - 12:15
Peter J. Houghton (St. Jude Children’s Hosp., Memphis, USA)
Target of rapamycin (mTOR): a novel therapeutic target for cancer treatment
12:15 - 12:35
Tetsuya Kamataki (Hokkaido Univ., Sapporo, Japan)
Pharmacogenetics of CYP2A6: Lung cancer risk related to tobacco smoking, and metabolism of tegafur to 5-FU
12:35 - 12:50
Discussion
12:50 - 14:00
Lunch Break
II New Drugs under Clinical Consideration (Part I)
Chairpersons: Ross C. Donehower (Johns Hopkins Univ., Baltimore, USA)
Masahiro Fukuoka (Kinki Univ., Osaka, Japan)
14:00 - 14:30
Mace L. Rothenberg (Vanderbilt Univ., Nashville, USA)
Oxaloplatin: a novel platinum active in colorectal cancer
14:30 - 14:50
Holger Beckmann (Tularik Inc., South San Francisco, USA)
Novel approach for the treatment of multidrug-resistant cancers
14:50 - 15:10
Maurizio D’Incalci (Istituto di Ricerche Farmacologiche, Milano, Italy)
ET-743, a marine natural product with unique pharmacological properties and promising clinical activity
15:10 - 15:30
David Parkinson (Novartis Pharma. Co., East Hanover, USA)
STI571
15:30 - 15:40
Discussion
15:40 - 16:00
Coffee Break
III New Drugs under Clinical Consideration (Part II)
Chairpersons: Stanley B. Kaye (Univ. Glasgow, Glasgow, U.K.)
Yutaka Ariyoshi (Aichi Hospital, Nagoya, Japan)
16:00 - 16:20
Kazuhiko Nakagawa (Kinki Univ., Osaka, Japan)
ZD-1839
16:20 - 16:40
Noboru Horikoshi (Cancer Inst. Hosp., Tokyo, Japan)
TZT-1027
16:40 - 17:10
Eric Raymond (Institut Gustave-Roussy, Villejuif, France)
CCI-779, an ester analogue of rapamycin that interacts with PTEN/PI3 kinase pathways: a phase I and pharmacokinetic study utilizing a weekly intravenous schedule
17:10 - 17:40
Leonard Neckers (NCI, Bethesda, USA)
Preclinical and early clinical studies with 17-allylamino-17-demethoxy geldanamycin (17AAG)
17:40 - 18:00
Discussion
18:00 - 19:00
Mixer
November 30, 2000 (Thu)
IV New Immunological Approaches for Cancer Treatment
Chairpersons: Herbert M. Pinedo (Free Univ., Amsterdam, Netherlands)
Ryuzo Ueda (Nagoya City Univ., Nagoya, Japan)
09:30 - 09:50
Hiroshi Shiku (Mie Univ., Tsu, Japan)
Immunological cell therapy for cancer
09:50 - 10:20
Herbert M. Pinedo (Free Univ., Amsterdam, Netherlands)
The Spinoza trial: Longterm neo-adjuvant chemo-immunotherapy including GM-CSF
10:20 - 10:50
David G. Maloney (Fred Hutchinson Cancer Research Center, Seattle, USA)
Rituximab: Anti-CD20 antibody therapy of lymphoma
10:50 - 11:00
Discussion
11:00 - 11:20
Coffee Break
V New Strategy for Chemotherapy with Target-based Drugs
Chairpersons: Mace L. Rothenberg (Vanderbilt Univ., Nashville, USA)
Nagahiro Saijo (National Cancer Center Hosp., Tokyo, Japan)
11:20 - 11:50
Ross C. Donehower (Johns Hopkins Univ., Baltimore, USA)
New agents directed against tubulin and microtubles
11:50 - 12:20
Stanley B. Kaye (Univ. Glasgow, Glasgow, U.K.)
Novel approaches to overcome drug resistance
12:20 - 12:50
Michaele C. Christian (NCI, Bethesda, USA)
Assessing the effects of drugs on their putative targets
12:50 - 13:00
Discussion
13:00 - 13:10
Takashi Tsuruo (Univ. Tokyo, Tokyo, Japan)
Closing Remark
